Results about: drug modelling
Nostrum BioDiscovery has come about from the combined efforts of IRB Barcelona and the BSC-CNS—two research centres of excellence in Barcelona—with the participation of the University of Barcelona and ICREA and supported by the Botín Foundation’s technology transfer programme.
The company boasts cutting-edge bioinformatics technologies to speed up the development and lower the cost of designing drugs—which are becoming increasingly more complex and expensive—and to further precision medicine.
The findings of an IRB Barcelona study challenge a scientific principle about amyloid beta, a protein linked to Alzheimer’s disease
Natàlia Carulla’s research group provides information that questions the widely accepted premise regarding the number of molecules and the shape of the first aggregates formed by amyloid beta protein
Amyloid beta protein aggregation, the process by which molecules of this protein adhere to each other is strongly associated with the development of Alzheimer’s disease
Carulla’s work ultimately seeks to identify molecules that interfere with the initial stages of aggregation as a strategy to combat the disease.
• The “Mind the Gap” programme selects Eduard Batlle and Elena Sancho to develop a diagnostic kit for patients at risk for metastasis, and Modesto Orozco to create a drug design platform.
• The IRB Barcelona projects, two of the three chosen by the Foundation, will receive one million euros of funding as well as management, coordination and consulting support for two years.
• An international committee of experts in investment strategies for biotechnology and biomedicine praise the high potential for innovation and viability of the projects.